CD274 and non-small cell lung carcinoma: In the KEYNOTE-024 study, pembrolizumab provided meaningful survival benefits in both PFS (median 7.7 vs. 5.5 mo, HR = 0.50, 95% CI: 0.39–0.65) and OS (median 26.3 vs. 13.4 mo, HR = 0.62, 95% CI: 0.48–0.81) versus chemotherapy as first-line therapy for metastatic NSCLC with PD-L1 tumor proportion score greater than 50% [13].